An urgent need for adjuvant molecular therapy in pancreatic cancer by utilizing some chemical molecules or inhibitors. The challenge of meeting the expectations of this desired target product profile, a key question arises: how to combine the available treatment regimens and will these treatments are effective against pancreatic cancer? A variety of new investigational efforts have been used mono-targeted therapy, chemotherapy, and surgical resection for the treatment and prevention of pancreatic cancer. Surgical resection also increased the survival rate from 5% to over 25% in pancreatic cancer, but progression to late stage metastasis greatly minimized the impact of surgery, and thus need to be replaced with adjuvant therapies.
Once published open access, authorâs work will be made available online, ensuring the widest possible exposure of the authors research. Open Access publications are very important for communication of research findings worldwide.
Last date updated on October, 2020